Founder & CEO

Bene Ekine-Afolabi is a graduate of River State University of Science & Technology with a degree in Applied Biology (Medical Microbiology option); and an MRes degree from University of East London, United Kingdom. She had her PhD. study & worked at the Department of Natural Sciences, Middlesex University, UK. Trained in practical approach to toxicology in drug development (American College of Toxicology/British Toxicology Society). Bene does research in Microbiology, Molecular Biology and Cancer Research: Her current focus of research is in the Investigation of molecular mechanism of colorectal cancer development, EMT, and cell death. Bene was awarded part-sponsored training in High Impact Cancer Research & therapeutic and was awarded with Distinction by Harvard University (Harvard Medical School) . Their current project involves lead compound optimization in the development of novel therapeutic for colorectal cancer.